Skip to content

iCoat Medical’s CMO Dr. Alireza Biglarnia wins grant for transplant research

iCoat Medical, a clinical stage pharmaceutical company focusing on reducing and preventing ischemia reperfusion injuries (IRI) during organ transplantation, today announced the company’s Chief Medical Officer Dr. Alireza Biglarnia was one of five research doctors to receive a grant for their research in the field of transplantation from the Transplantationsfonden, a cooperation between Skåne University Hospital and the Skåne kidney care network.

“I’m grateful my research on the medical and health economic evaluation of a new surgical method was recognized by Transplantationsfonden this year,” said Dr. Biglarnia. “There are more than 200,000 transplants likely to be done in 2025, making research and new techniques critical to ensure these people get the best treatment possible. I’m confident iCoat Medical will play a key role in this important progress.”

The upcoming Phase 2b EMPIRe study is iCoat Medical’s next step in clinical development of its leading drug candidate iCM012 in deceased-donor kidney transplantation and is the logical next step to advance the successfully completed Phase 1/2a study ATMIRe. The upcoming study, which is planned to start in 2024, will include approximately 100 patients and be performed at selected high-quality sites in Europe and the U.S. The potential for conditional approval, given sufficiently convincing data generated by the Phase 2b study, will later be discussed with the regulatory authorities.

For more information, please contact:

Peder Waern, CEO – iCoat Medical AB
Mattias Springare, CFO and Head of Investor Relations – iCoat Medical AB

About iCoat Medical
iCoat Medical is a clinical stage, pharmaceutical company focusing on reducing and preventing ischemia reperfusion injuries by developing novel pharmaceutical products. The company is one of the world’s leading R&D-centered organizations within innate immunology and is systematically expanding its pipeline using its proprietary coating-technology platform. iCoat Medical’s lead candidate iCM012 is developed to improve the outcome of organ transplantations. The company’s unique ex-vivo coating of the grafts has the ambition of being an integral part in the transplant procedures of tomorrow. iCoat Medical has operations in Uppsala, Lund, and Malmö, and is headquartered in Stockholm.

For more information, please visit